Trials / Terminated
TerminatedNCT03915886
A Study of JNJ-64530440 in Healthy Japanese Male Participants
A Double-blind, Placebo-controlled, Randomized, Single Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-64530440 in Healthy Japanese Male Subjects
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Janssen Pharmaceutical K.K. · Industry
- Sex
- Male
- Age
- 20 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the safety, tolerability, and pharmacokinetics (PK) of JNJ-64530440 (JNJ-0440) in healthy Japanese adult male participants after single oral dose administration with ascending dose design.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JNJ-0440 | JNJ-0440 tablets will be administered orally. |
| DRUG | Placebo | Matching placebo tablets will be administered orally. |
Timeline
- Start date
- 2019-04-15
- Primary completion
- 2019-07-17
- Completion
- 2019-07-17
- First posted
- 2019-04-16
- Last updated
- 2025-02-03
Locations
1 site across 1 country: Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03915886. Inclusion in this directory is not an endorsement.